234 related articles for article (PubMed ID: 32269146)
1. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.
Abdul Sater H; Marté JL; Donahue RN; Walter-Rodriguez B; Heery CR; Steinberg SM; Cordes LM; Chun G; Karzai F; Bilusic M; Harmon SA; Turkbey IB; Choyke PL; Schlom J; Dahut WL; Madan RA; Pinto PA; Gulley JL
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32269146
[TBL] [Abstract][Full Text] [Related]
2. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.
Fong L; Carroll P; Weinberg V; Chan S; Lewis J; Corman J; Amling CL; Stephenson RA; Simko J; Sheikh NA; Sims RB; Frohlich MW; Small EJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25255802
[TBL] [Abstract][Full Text] [Related]
3. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
Farsaci B; Jochems C; Grenga I; Donahue RN; Tucker JA; Pinto PA; Merino MJ; Heery CR; Madan RA; Gulley JL; Schlom J
Int J Cancer; 2014 Aug; 135(4):862-70. PubMed ID: 24474335
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
5. High intratumoral CD8
Yang Y; Attwood K; Bshara W; Mohler JL; Guru K; Xu B; Kalinski P; Chatta G
Prostate; 2021 Jan; 81(1):20-28. PubMed ID: 33085799
[TBL] [Abstract][Full Text] [Related]
6. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
Obradovic AZ; Dallos MC; Zahurak ML; Partin AW; Schaeffer EM; Ross AE; Allaf ME; Nirschl TR; Liu D; Chapman CG; O'Neal T; Cao H; Durham JN; Guner G; Baena-Del Valle JA; Ertunc O; De Marzo AM; Antonarakis ES; Drake CG
Clin Cancer Res; 2020 Jul; 26(13):3182-3192. PubMed ID: 32173650
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer.
Ryan ST; Zhang J; Burner DN; Liss M; Pittman E; Muldong M; Shabaik A; Woo J; Basler N; Cunha J; Shalapour S; Estrada MV; Karin M; Messer K; Howell S; Kane CJ; Jamieson CAM
J Transl Med; 2020 May; 18(1):214. PubMed ID: 32466781
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance.
Parsons JK; Pinto PA; Pavlovich CP; Uchio E; Nguyen MN; Kim HL; Gulley JL; Sater HA; Jamieson C; Hsu CH; Wojtowicz M; House M; Schlom J; Donahue RN; Dahut WL; Madan RA; Bailey S; Centuori S; Bauman JE; Parnes HL; Chow HS
Eur Urol Focus; 2023 May; 9(3):447-454. PubMed ID: 36517408
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer.
Vuky J; Corman JM; Porter C; Olgac S; Auerbach E; Dahl K
Oncologist; 2013 Jun; 18(6):687-8. PubMed ID: 23740935
[TBL] [Abstract][Full Text] [Related]
11. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
12. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
[TBL] [Abstract][Full Text] [Related]
13. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.
Wei XX; Chan S; Kwek S; Lewis J; Dao V; Zhang L; Cooperberg MR; Ryan CJ; Lin AM; Friedlander TW; Rini B; Kane C; Simko JP; Carroll PR; Small EJ; Fong L
Cancer Immunol Res; 2016 Nov; 4(11):948-958. PubMed ID: 27688020
[TBL] [Abstract][Full Text] [Related]
14. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
Andersen LB; Nørgaard M; Rasmussen M; Fredsøe J; Borre M; Ulhøi BP; Sørensen KD
J Pathol; 2021 Oct; 255(2):155-165. PubMed ID: 34255349
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
[TBL] [Abstract][Full Text] [Related]
16. T cells CD4+/CD8+ local immune modulation by prostate cancer hemi-cryoablation.
Cerqueira MA; Ferrari KL; de Mattos AC; Monti CR; Reis LO
World J Urol; 2020 Mar; 38(3):673-680. PubMed ID: 31263944
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.
Garcia JA; Klein EA; Magi-Galluzzi C; Elson P; Triozzi P; Dreicer R
Clin Cancer Res; 2008 May; 14(10):3052-9. PubMed ID: 18483371
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
[TBL] [Abstract][Full Text] [Related]
20. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
Daiko H; Marafioti T; Fujiwara T; Shirakawa Y; Nakatsura T; Kato K; Puccio I; Hikichi T; Yoshimura S; Nakagawa T; Furukawa M; Stoeber K; Nagira M; Ide N; Kojima T
Cancer Immunol Immunother; 2020 Nov; 69(11):2247-2257. PubMed ID: 32500232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]